Biomarkers in Duchenne Muscular Dystrophy

Theo Lee-Gannon; Xuan Jiang; Tara C. Tassin; Pradeep P.A. Mammen

doi:10.1007/s11897-022-00541-6

Biomarkers in Duchenne Muscular Dystrophy

Theo Lee-Gannon, Xuan Jiang, Tara C. Tassin, Pradeep P.A. Mammen

Research output: Contribution to journal › Review article › peer-review

5 Scopus citations

Abstract

Purpose of Review: This review highlights the key studies investigating various types of biomarkers in Duchenne muscular dystrophy (DMD). Recent Findings: Several proteomic and metabolomic studies have been undertaken in both human DMD patients and animal models of DMD that have identified potential biomarkers in DMD. Summary: Although there have been a number of proteomic and metabolomic studies that have identified various potential biomarkers in DMD, more definitive studies still need to be undertaken in DMD patients to firmly correlate these biomarkers with diagnosis, disease progression, and monitoring the effects of novel treatment strategies being developed.

Original language	English (US)
Pages (from-to)	52-62
Number of pages	11
Journal	Current heart failure reports
Volume	19
Issue number	2
DOIs	https://doi.org/10.1007/s11897-022-00541-6
State	Published - Apr 2022

Keywords

Biomarkers
DMD-associated cardiomyopathy
Duchenne muscular dystrophy
Metabolomics
Proteomics

ASJC Scopus subject areas

Emergency Medicine
Cardiology and Cardiovascular Medicine
Physiology (medical)

Access to Document

10.1007/s11897-022-00541-6

Cite this

@article{720c4bf4672342ce8f1b423b68e3cd95,

title = "Biomarkers in Duchenne Muscular Dystrophy",

abstract = "Purpose of Review: This review highlights the key studies investigating various types of biomarkers in Duchenne muscular dystrophy (DMD). Recent Findings: Several proteomic and metabolomic studies have been undertaken in both human DMD patients and animal models of DMD that have identified potential biomarkers in DMD. Summary: Although there have been a number of proteomic and metabolomic studies that have identified various potential biomarkers in DMD, more definitive studies still need to be undertaken in DMD patients to firmly correlate these biomarkers with diagnosis, disease progression, and monitoring the effects of novel treatment strategies being developed.",

keywords = "Biomarkers, DMD-associated cardiomyopathy, Duchenne muscular dystrophy, Metabolomics, Proteomics",

author = "Theo Lee-Gannon and Xuan Jiang and Tassin, {Tara C.} and Mammen, {Pradeep P.A.}",

note = "Publisher Copyright: {\textcopyright} 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.",

year = "2022",

month = apr,

doi = "10.1007/s11897-022-00541-6",

language = "English (US)",

volume = "19",

pages = "52--62",

journal = "Current heart failure reports",

issn = "1546-9530",

publisher = "Current Science, Inc.",

number = "2",

}

TY - JOUR

T1 - Biomarkers in Duchenne Muscular Dystrophy

AU - Lee-Gannon, Theo

AU - Jiang, Xuan

AU - Tassin, Tara C.

AU - Mammen, Pradeep P.A.

PY - 2022/4

Y1 - 2022/4

N2 - Purpose of Review: This review highlights the key studies investigating various types of biomarkers in Duchenne muscular dystrophy (DMD). Recent Findings: Several proteomic and metabolomic studies have been undertaken in both human DMD patients and animal models of DMD that have identified potential biomarkers in DMD. Summary: Although there have been a number of proteomic and metabolomic studies that have identified various potential biomarkers in DMD, more definitive studies still need to be undertaken in DMD patients to firmly correlate these biomarkers with diagnosis, disease progression, and monitoring the effects of novel treatment strategies being developed.

AB - Purpose of Review: This review highlights the key studies investigating various types of biomarkers in Duchenne muscular dystrophy (DMD). Recent Findings: Several proteomic and metabolomic studies have been undertaken in both human DMD patients and animal models of DMD that have identified potential biomarkers in DMD. Summary: Although there have been a number of proteomic and metabolomic studies that have identified various potential biomarkers in DMD, more definitive studies still need to be undertaken in DMD patients to firmly correlate these biomarkers with diagnosis, disease progression, and monitoring the effects of novel treatment strategies being developed.

KW - Biomarkers

KW - DMD-associated cardiomyopathy

KW - Duchenne muscular dystrophy

KW - Metabolomics

KW - Proteomics

UR - http://www.scopus.com/inward/record.url?scp=85127625423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85127625423&partnerID=8YFLogxK

U2 - 10.1007/s11897-022-00541-6

DO - 10.1007/s11897-022-00541-6

M3 - Review article

C2 - 35386072

AN - SCOPUS:85127625423

SN - 1546-9530

VL - 19

SP - 52

EP - 62

JO - Current heart failure reports

JF - Current heart failure reports

IS - 2

ER -

Biomarkers in Duchenne Muscular Dystrophy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this